Prophylactic effect of a therapeutic vaccine against tb based on fragments of mycobacterium tuberculosis

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Vilaplana, Cristina ^a,b   Gil, Olga ^a,b   Cáceres, Neus ^a,b   Pinto, Sergio ^a,b   Díaz, Jorge ^a,b   Cardona, Pere Joan ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; RUTI; UNCLASSIFIED DRUG; BACTERIAL VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BACTERIAL VIRULENCE; BCG VACCINATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GUINEA PIG; INFECTION PREVENTION; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SINGLE DRUG DOSE; ANIMAL; CYTOLOGY; IMMUNOLOGY; METHODOLOGY; TIME; TUBERCULOSIS; VACCINATION;

BACILLI (CLASS); BACTERIA (MICROORGANISMS); CAVIA; MUS; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; BACTERIAL VACCINES; FEMALE; GUINEA PIGS; MICE; MYCOBACTERIUM TUBERCULOSIS; TIME FACTORS; TUBERCULOSIS; VACCINATION;

EID: 79957513630     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020404     Document Type: Article

References (23)

1. WHO (2009) Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. Geneva, Switzerland.
2. Marais B, Raviglione M, Donald P, Harries A, Kritski A, et al. (2010) Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet.
3. Kaufmann S, Hussey G, Lambert P, (2010) New vaccines for tuberculosis. Lancet 375: 2110-2119.
4. Cardona PJ, (2006) RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 86: 273-289.
5. Kaufmann S, (2007) The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 5: 491-504.
6. Fine P, (2005) Stopping routine vaccination for tuberculosis in schools. BMJ 331: 647-648.
7. Azzopardi P, Bennett C, Graham S, Duke T, (2009) Bacille Calmette-Guérin vaccine-related disease in HIV-infected children: a systematic review. Int J Tuberc Lung Dis 13: 1331-1344.
8. Hesseling A, Cotton M, Fordham von Reyn C, Graham S, Gie R, et al. (2008) Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 12: 1376-1379.
9. Hesseling A, Johnson L, Jaspan H, Cotton M, Whitelaw A, et al. (2009) Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. Bull World Health Organ 87: 505-511.
10. TB Vaccines Pipeline.(2009) Stop TB Partnership Working Group on New TB Vaccines.
11. Beresford B, Sadoff JC, (2010) Update on research and development pipeline: tuberculosis vaccines. Clin Infect Dis 50 (Suppl 3): S178-183.
12. McShane H, (2009) Vaccine strategies against tuberculosis. Swiss Med Wkly 139: 156-160.
13. Guirado E, Gil O, Caceres N, Singh M, Vilaplana C, et al. (2008) Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. Clin Vaccine Immunol 15: 1229-1237.
14. Cardona PJ, Amat I, Gordillo S, Arcos V, Guirado E, et al. (2005) Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 23: 1393-1398.
15. Domingo M, Gil O, Serrano E, Guirado E, Nofrarias M, et al. (2009) Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Mycobacterium tuberculosis cells' fragments: field-study with naturally Mycobacterium caprae-infected goats. Scand J Immunol 69: 500-507.
16. Gil O, Vilaplana C, Guirado E, Díaz J, Cáceres N, et al. (2008) Enhanced gamma interferon responses of mouse spleen cells following immunotherapy for tuberculosis relapse. Clin Vaccine Immunol 15: 1742-1744.
17. Gil O, Díaz I, Vilaplana C, Tapia G, Díaz J, et al. (2010) Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs. PLoS One 5: e10030.
18. Vilaplana C, Montané E, Pinto S, Barriocanal AM, Domenech G, et al. (2010) Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. Vaccine 28: 1106-1116.
19. Orme I, (2006) Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 24: 2-19.
20. Moreira AL, Tsenova L, Aman MH, Bekker LG, Freeman S, et al. (2002) Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect Immun 70: 2100-2107.
21. Rook GA, Stanford JL, (1996) The Koch phenomenon and the immunopathology of tuberculosis. Curr Top Microbiol Immunol 215: 239-262.
22. Horwitz M, Harth G, Dillon B, Maslesa-Galic' S, (2000) Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97: 13853-13858.
23. Martínez A, Calpe JL, Llavador G, Ena J, Calpe A, (2005) Primary Prevention and Treatment of Latent Tuberculosis Infection With Isoniazid: Efficacy of a Control Program, 1997-2002. Archivos de Bronconeumologia pp. 27-33.